Eli Lilly and Company (NYSE: LLY) agreed on July 16 to acquire AtaiBeckley Inc. (NASDAQ: ATAI), gaining BPL-003, an investigational intranasal mebufotenin benzoate therapy that has initiated Phase 3 activities for treatment-resistant depression, along with the Phase 2 VLS-01 dimethyltryptamine program. Eli Lilly will pay US$6.75 per AtaiBeckley share in cash at closing, representing an aggregate equity value of approximately US$2.8 billion, with contingent value rights potentially adding another US$2.50 per share, or approximately US$1 billion.
The distinction between the amount payable at closing and the maximum potential consideration is essential. Eli Lilly has not already paid US$3.8 billion, and AtaiBeckley shareholders will receive the additional amount only if defined development, regulatory approval and Drug Enforcement Administration rescheduling milestones are reached.
The proposed acquisition is expected to close during the third quarter of 2026, subject to AtaiBeckley shareholder approval, regulatory clearances and other customary conditions. Both boards have approved the transaction, while AtaiBeckley directors, officers and Apeiron Investment Group have agreed to support the deal with shares representing approximately 15% of the company’s outstanding stock.
Why did Eli Lilly attach US$1 billion of the purchase price to future clinical and regulatory outcomes?
The contingent value right structure divides the scientific and regulatory risk between Eli Lilly and AtaiBeckley shareholders. It allows Eli Lilly to secure the company and its pipeline while limiting the amount paid before the most important clinical and regulatory questions have been answered.
AtaiBeckley shareholders could receive US$1 per share if a Phase 3 trial of VLS-01 begins before the fourth anniversary of the acquisition’s closing. Another US$0.50 per share depends on BPL-003 receiving United States regulatory approval and completing the required Drug Enforcement Administration rescheduling before the fifth anniversary. The final US$1 per share is linked to approval and rescheduling of VLS-01 before the seventh anniversary.
Those conditions show that Eli Lilly is acquiring more than one late-stage depression candidate. BPL-003 is the most advanced asset, but VLS-01 accounts for US$2 of the maximum US$2.50 contingent value right. VLS-01 is a buccal-film formulation of dimethyltryptamine being evaluated in the randomized, double-blind, placebo-controlled Phase 2 Elumina study for treatment-resistant depression, with topline data anticipated during the fourth quarter of 2026.
The structure also acknowledges that regulatory approval alone may not be enough for commercial launch. Psychedelic compounds that are currently controlled under Schedule I would require a separate federal rescheduling process after approval. The timetable, conditions and operational implications of that process could affect when a therapy reaches certified treatment centres and begins generating revenue.
How strong is the Phase 2b evidence supporting BPL-003 before two pivotal trials read out?
BPL-003 is a proprietary intranasal formulation of mebufotenin benzoate, also known as 5-MeO-DMT. It is being developed as a short-duration, clinic-administered treatment for adults with treatment-resistant depression and has received Breakthrough Therapy designation from the United States Food and Drug Administration. That designation can support closer regulatory interaction, but it is not approval and does not establish that the candidate is safe or effective.
The completed Phase 2b core study randomized 193 participants to a single 8 milligram, 12 milligram or 0.3 milligram dose. The low dose served as an active comparator intended to reduce expectancy effects, an important design consideration because the noticeable perceptual effects of psychedelic compounds can reveal treatment allocation to participants, staff and raters even in a masked trial.
At Day 29, the company reported a mean reduction from baseline of 12.1 points on the Montgomery-Åsberg Depression Rating Scale for the 8 milligram group and 11.1 points for the 12 milligram group, compared with a 5.8-point reduction for the 0.3 milligram comparator. Both active groups achieved statistical significance against the comparator, with reported p-values of 0.0025 and 0.0038, respectively. Differences were also reported at Day 2, while the reduction in symptoms remained evident through the Day 57 assessment.
The randomized design, central blinded raters and active comparator strengthen the evidence relative to small open-label psychedelic studies. However, much of the detailed Phase 2b evidence remains available through company disclosures rather than a complete peer-reviewed publication. Functional unblinding also remains difficult to eliminate when participants can distinguish higher psychedelic doses from a low-dose comparator.
More than 99% of treatment-emergent adverse events in the blinded core study were classified as mild or moderate, and the company reported no drug-related serious adverse events in that portion of the trial. In the subsequent open-label extension, 107 participants received a second 12 milligram dose eight weeks after the first administration. One serious drug-related adverse event was reported eight days after the second dose and resolved following additional inpatient monitoring and support.
The Phase 3 ReConnection programme is designed to move beyond those limitations. ReConnection-1 is expected to enrol approximately 350 participants, while ReConnection-2 is expected to include about 230. Both pivotal studies use change from baseline in the Montgomery-Åsberg Depression Rating Scale at Week 4 as the primary endpoint and include a 52-week open-label extension evaluating longer-term safety, durability and individualized retreatment at eight-week or 12-week intervals. Topline Phase 3 results are expected in early 2029.
Can a two-hour psychedelic treatment model fit existing interventional psychiatry workflows?
BPL-003’s commercial attraction is not based solely on its pharmacology. AtaiBeckley is trying to fit the candidate into an approximately two-hour treatment model, potentially making it more manageable for clinics than psychedelic therapies that require much longer supervised sessions.
The company has reported that participants generally met readiness-for-discharge criteria within two hours after dosing. That duration could allow an established interventional psychiatry centre to conduct more treatment sessions per room and per clinician than would be practical with therapies requiring most of a working day.
Johnson & Johnson’s Spravato has already established a partial operational precedent for clinic-administered mental health treatment. Spravato is an esketamine product rather than a classic psychedelic, but it must be administered in certified healthcare settings under a Risk Evaluation and Mitigation Strategy, with patients monitored for at least two hours. That existing infrastructure could provide a starting point for BPL-003 if it is approved with comparable controls.
Shorter duration does not eliminate the commercial burden. Clinics may still require trained monitors, dedicated rooms, emergency procedures, controlled-substance storage, patient transport arrangements and post-treatment follow-up. The final label, potential Risk Evaluation and Mitigation Strategy, reimbursement model and frequency of repeat dosing will determine whether the two-hour concept produces a sustainable service model.
Payers will also need to assess more than the acquisition cost of the drug. A complete treatment episode could include preparation, administration, clinical monitoring and follow-up. Eli Lilly’s market access and commercial infrastructure may help solve those problems, but reimbursement will ultimately depend on evidence that benefits are sufficiently durable to justify the combined drug and service cost.
Why does the FDA’s final psychedelic guidance clarify the path without lowering the approval bar?
The United States Food and Drug Administration finalized its guidance for psychedelic drug clinical investigations in July 2026, two days before Eli Lilly announced the AtaiBeckley agreement. The timing improved regulatory visibility, but the guidance does not create a separate or reduced evidentiary standard for psychedelic therapies.
The agency emphasized functional unblinding, expectancy bias, dose selection, abuse-potential assessment, longer-term follow-up and the difficulty of separating a drug’s effect from psychological support or psychotherapy. It encouraged appropriate control groups, blinded independent raters and study designs capable of determining which component of a combined intervention contributes to an observed outcome.
For chronic conditions such as major depressive disorder, regulators are likely to examine whether an apparent early response remains durable, whether symptoms return, and whether repeated treatment creates new safety or operational concerns. BPL-003’s four-week pivotal endpoint will consequently need to be interpreted alongside its longer follow-up and retreatment evidence.
The sector has already seen why regulatory enthusiasm cannot substitute for trial quality. The United States Food and Drug Administration issued Lykos Therapeutics a complete response letter in 2024 for its midomafetamine application in post-traumatic stress disorder and requested an additional Phase 3 study. That decision demonstrated that Breakthrough Therapy designation, severe unmet need and supportive policy attention do not overcome concerns involving trial design, bias, safety documentation or evidence durability.
Federal measures announced in 2026 may accelerate reviews and improve inter-agency coordination, particularly for candidates with Breakthrough Therapy designation. They do not guarantee that BPL-003, VLS-01 or any competing psychedelic candidate will receive approval.
Does the AtaiBeckley acquisition genuinely reprice other psychedelic medicine developers?
Eli Lilly’s agreement is a significant price-setting event, but it is not the psychedelic field’s first large-pharma endorsement. AbbVie Inc. completed the acquisition of Gilgamesh Pharmaceuticals’ bretisilocin programme in October 2025 under a transaction valued at up to US$1.2 billion. Bretisilocin is a short-acting investigational psychedelic compound in Phase 2 development for major depressive disorder.
The AtaiBeckley transaction is larger and includes a broader clinical portfolio. It therefore strengthens the argument that major pharmaceutical companies will consider owning psychedelic drug programmes when the assets have differentiated intellectual property, credible clinical evidence and a delivery model designed for existing healthcare infrastructure.
AtaiBeckley shares closed at US$7.19 on July 20, above the US$6.75 cash consideration but below the maximum US$9.25 value if every contingent milestone is achieved. The price embeds some expectation of contingent value, although it also reflects the time required to close the deal, transaction risk and uncertainty surrounding the milestone payments.
The shares gained approximately 44.7% over the five trading sessions ending July 20 and about 77.5% over one month, moving close to the top of their US$3.06 to US$7.22 52-week range. This is now principally an event-driven stock, with its value tied to transaction completion and the market’s assessment of the contingent value rights.
Eli Lilly shares closed at US$1,146.90 on July 20, down approximately 3% over five sessions but up about 4.1% over one month. The shares remained toward the upper end of their US$623.78 to US$1,249.45 52-week range. Given Eli Lilly’s market value of more than US$1 trillion, the AtaiBeckley acquisition is strategically interesting but too small by itself to dominate the investment case.
The wider sector reaction was less uniform than some early commentary suggested. Compass Pathways plc opened sharply higher on July 16 but closed 6.6% lower, while Definium Therapeutics Inc. also surrendered an early gain and finished the session down 3.4%. GH Research PLC, whose lead programme is also based on mebufotenin, recorded a stronger positive reaction. The mixed closes indicate that investors distinguished between individual pipelines rather than applying the AtaiBeckley valuation indiscriminately.
Helus Pharma Inc. (NASDAQ: HELP) provides another important test of the read-across. Its shares rose 8.1% on July 16 and closed at US$7.11 on July 20, representing a five-session gain of approximately 6.1% and a one-month increase of about 46.6%. The stock remained within a 52-week range of US$3.76 to US$9.12.
Helus Pharma’s value, however, remains tied to its own evidence. HLP003 is a deuterated psilocin analogue in Phase 3 development as an adjunctive treatment for major depressive disorder. The APPROACH study had surpassed 88% enrolment by late June, with topline data expected in the fourth quarter of 2026, while the second pivotal EMBRACE study is enrolling.
The Eli Lilly transaction does not establish clinical validation for HLP003, create a disclosed relationship with Helus Pharma or imply acquisition interest. A positive Phase 3 result could materially strengthen the programme, but the trial must still demonstrate its prespecified efficacy endpoint, an acceptable safety profile and evidence capable of supporting the planned broader regulatory package.
What must happen before Eli Lilly’s AtaiBeckley deal reaches its full US$3.8 billion value?
The first test is completion of the acquisition, currently targeted for the third quarter. AtaiBeckley shareholders must approve the transaction, and the parties must obtain the necessary regulatory clearances.
Clinical attention will then turn to the VLS-01 Elumina Phase 2 result expected in the fourth quarter of 2026 and execution of the BPL-003 ReConnection studies through their planned early-2029 readouts. Eli Lilly must also integrate the AtaiBeckley team, preserve specialised development capabilities and determine how the pipeline fits within its broader neuroscience organisation.
Reaching the maximum transaction value would require more than promising clinical signals. VLS-01 must enter Phase 3 within the specified period, BPL-003 must obtain United States approval and rescheduling, and VLS-01 must ultimately complete the same approval and rescheduling sequence. Failure at any point could reduce or eliminate part of the contingent payment.
The acquisition makes a credible exit pathway more visible for psychedelic biotechnology companies and provides a substantial benchmark for clinically advanced, short-duration assets. It does not make the category clinically proven. Eli Lilly is committing approximately US$2.8 billion at closing, while the remaining US$1 billion will be earned only if the trials, regulators and controlled-substance process deliver what market enthusiasm alone cannot.
